1-9 of 9
Paolo Ghia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Clinical Trials & Observations
Matthew S. Davids, Jeff P. Sharman, Paolo Ghia, Jennifer A. Woyach, Toby A. Eyre, Wojciech Jurczak, Tanya Siddiqi, Paulo Miranda, Mina Shahkarami, Anna Butturini, Ugochinyere Emeribe, John C. Byrd
Journal: Blood Advances
Blood Adv (2024) 8 (13): 3345–3359.
https://doi.org/10.1182/bloodadvances.2023011307
Published: 2024
Includes: Supplemental data
Journal Articles

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Silvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, Antonella Capasso, Tatjana Pandzic, Simone Weström, Hassan Foroughi-Asl, Aron Skaftason, Anna Gellerbring, Anna Lyander, Francesca Gandini, Gianluca Gaidano, Livio Trentin, Lisa Bonello, Gianluigi Reda, Csaba Bödör, Niki Stavroyianni, Constantine S. Tam, Roberto Marasca, Francesco Forconi, Panayiotis Panayiotidis, Ingo Ringshausen, Ozren Jaksic, Anna Maria Frustaci, Sunil Iyengar, Marta Coscia, Stephen P. Mulligan, Loïc Ysebaert, Vladimir Strugov, Carolina Pavlovsky, Renata Walewska, Anders Österborg, Diego Cortese, Pamela Ranghetti, Panagiotis Baliakas, Kostas Stamatopoulos, Lydia Scarfò, Richard Rosenquist, Paolo Ghia
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2794–2806.
https://doi.org/10.1182/bloodadvances.2022008821
Published: 2023
Includes: Supplemental data
Journal Articles

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

Giorgia Chiodin, Samantha Drennan, Enrica A. Martino, Laura Ondrisova, Isla Henderson, Luis del Rio, Ian Tracy, Annalisa D’Avola, Helen Parker, Silvia Bonfiglio, Lydia Scarfò, Lesley-Ann Sutton, Jonathan C. Strefford, Jade Forster, Oliver Brake, Kathleen N. Potter, Benjamin Sale, Stuart Lanham, Marek Mraz, Paolo Ghia, Freda K. Stevenson, Francesco Forconi
Journal: Blood Advances
Blood Adv (2022) 6 (18): 5494–5504.
https://doi.org/10.1182/bloodadvances.2021006659
Published: 2022
Includes: Supplemental data
Journal Articles

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial

Lydia Scarfò, Silvia Ferrari, Anna Maria Frustaci, Monica Tani, Alessia Bari, Eloise Scarano, Maria Colia, Pamela Ranghetti, Piera Angelillo, Paola Ronchi, Maurilio Ponzoni, Andrés J. M. Ferreri, Paolo Ghia
Journal: Blood Advances
Blood Adv (2022) 6 (18): 5356–5359.
https://doi.org/10.1182/bloodadvances.2022007138
Published: 2022
Includes: Supplemental data
Journal Articles

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steve E. Coutre, Claire Dearden, Sebastian Grosicki, Helen McCarthy, Jian-Yong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szoke, Thomas J. Kipps, Paolo Ghia
Journal: Blood Advances
Blood Adv (2022) 6 (11): 3440–3450.
https://doi.org/10.1182/bloodadvances.2021006434
Published: 2022
Includes: Supplemental data
Journal Articles

Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Yair Herishanu, Irit Avivi, Shai Levi, Gabi Shefer, Yotam Bronstein, Miguel Morales Moshiashvili, Tomer Ziv, Lydia Scarfò, Chava Perry, Paolo Ghia
Journal: Blood Advances
Blood Adv (2022) 6 (1): 148–151.
https://doi.org/10.1182/bloodadvances.2021005998
Published: 2022
Includes: Supplemental data
Journal Articles

CD4 + T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism

Matteo Grioni, Arianna Brevi, Elena Cattaneo, Alessandra Rovida, Jessica Bordini, Maria Teresa Sabrina Bertilaccio, Maurilio Ponzoni, Giulia Casorati, Paolo Dellabona, Paolo Ghia, Matteo Bellone, Arianna Calcinotto
Journal: Blood Advances
Blood Adv (2021) 5 (14): 2817–2828.
https://doi.org/10.1182/bloodadvances.2020003795
Published: 2021
Journal Articles

Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia

Elisavet Chartomatsidou, Stavroula Ntoufa, Konstantia Kotta, Alessandra Rovida, Maria Anna Akritidou, Daniela Belloni, Elisabetta Ferrero, Theoni Trangas, Niki Stavroyianni, Achilles Anagnostopoulos, Richard Rosenquist, Paolo Ghia, Nikos Papakonstantinou, Kostas Stamatopoulos
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1891–1896.
https://doi.org/10.1182/bloodadvances.2018030262
Published: 2019
Includes: Supplemental data
Journal Articles

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Clinical Trials & Observations
Steven E. Coutre, John C. Byrd, Peter Hillmen, Jacqueline C. Barrientos, Paul M. Barr, Stephen Devereux, Tadeusz Robak, Thomas J. Kipps, Anna Schuh, Carol Moreno, Richard R. Furman, Jan A. Burger, Michael O’Dwyer, Paolo Ghia, Rudolph Valentino, Stephen Chang, James P. Dean, Danelle F. James, Susan M. O’Brien
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1799–1807.
https://doi.org/10.1182/bloodadvances.2018028761
Published: 2019
Includes: Supplemental data